TLR7 and neoplasm: In addition, since the enhancement of the anti-tumor effect by combination of RT with TLR7 agonist was reported to be dependent on the irradiation dose [21, 22], we evaluated the anti-tumor activity of DSP-0509 (5 mg/kg q1w i.v.)combined with RT (2 Gy x 5 days) or RT (7 Gy x 5 days) in the subcutaneous LM8 tumor-bearing mouse model.